Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer.

ABSTRACT:

Purpose

Prostate cancer is the second leading cause of cancer death in men in the US. Since 2015, landmark studies have demonstrated improved survival outcomes with the use of docetaxel (DCT) or abiraterone (AA) in addition to androgen deprivation therapy (ADT) in the metastatic hormone-naïve setting. These treatment strategies have not been prospectively compared but have similar overall survival benefits despite differing mechanisms of action, toxicity, and cost. We performed a cost-effectiveness analysis to provide insight into the value of AA vs. DCT in the first-line treatment of metastatic prostate cancer.

Materials and methods

We developed Markov models by using a US-payer perspective and a 3-year time horizon to estimate costs (2018 US$) and progression-free quality-

SUBMITTER: Ramamurthy C 

PROVIDER: S-EPMC7751618 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature